Internal Medicine, Hematology & Oncology · New York, NY
NPI
1649253675
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
10 Union Sq E, Suite 4c
New York, NY, 10003
Phone (212) 844-8948
Groups this clinician bills Medicare through
Medicare paid, 2024
$63K
832 services
Medicare patients, 2024
258
Average age 75
Drug cost, 2024
$6.8M
1,253 prescriptions
Company payments, 2025
$7,767
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ilan Shapira was code 99214 (office e&m - established), 649 times for 225 patients. In total Ilan Shapira billed 832 services in 11 codes, and Medicare paid $63K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-10-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 649 | 225 | $76.69 | $50K |
| 99213 Office E&M - Established | Office | 84 | 37 | $48.15 | $4,045 |
| 99205 Office E&M - New | Office | 34 | 34 | $144.37 | $4,908 |
| 38222 Other Organ Systems | Office | 22 | 22 | $65.10 | $1,432 |
| 99212 Office E&M - Established | Office | 15 | 12 | $30.64 | $460 |
| 99215 Office E&M - Established | Office | 11 | 11 | $125.60 | $1,382 |
By year: 2022 $71K for 1,008 services; 2023 $64K for 832 services; 2024 $63K for 832 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ilan Shapira prescribed most often to Medicare patients was Revlimid (Lenalidomide), with 101 prescriptions and refills. In total Ilan Shapira wrote 1,253 Medicare prescriptions that cost $6.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | 101 | 101 | 17 | $1.7M |
| Valacyclovir Valacyclovir Hcl | 100 | 133 | 29 | $2,108 |
| Imatinib Mesylate Generic | 74 | 78 | Under 11 | $15K |
| Imbruvica Ibrutinib | 68 | 68 | Under 11 | $1.1M |
| Hydroxyurea Generic | 63 | 97 | 13 | $1,308 |
| Lenalidomide Generic | 59 | 59 | 11 | $781K |
| Ninlaro Ixazomib Citrate | 55 | 55 | Under 11 | $683K |
| Xarelto Rivaroxaban | 54 | 70 | Under 11 | $38K |
| Dexamethasone Generic | 45 | 51 | 12 | $1,124 |
| Prednisone Generic | 41 | 45 | 11 | $99.46 |
| Eliquis Apixaban | 40 | 60 | Under 11 | $33K |
| Procrit Epoetin Alfa | 36 | 36 | 11 | $124K |
| Prochlorperazine Maleate Generic | 31 | 31 | 19 | $250 |
| Promacta Eltrombopag Olamine | 30 | 30 | Under 11 | $267K |
| Oxycodone Hcl Generic | 30 | 30 | Under 11 | $775 |
Brand drugs: - claims; generic drugs: 704 claims; opioid claims: 47.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ilan Shapira $7,767 ($7,767 in general payments such as food, travel and fees) from 13 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $7,209.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $7,209 |
| Janssen Biotech, Inc. JNJ | 4 | $100 |
| Celgene Corporation BMY | 5 | $75.19 |
| Alexion Pharmaceuticals, Inc. AZN | 2 | $68.71 |
| Abbvie Inc. ABBV | 2 | $60.5 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $51.37 |
| Karyopharm Therapeutics Inc. KPTI | 2 | $46.65 |
| GlaxoSmithKline, LLC. GSK | 2 | $38.07 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $26.39 |
| Daiichi Sankyo Inc. 4568.T | 1 | $25.71 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.